HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Diamandis, E. P. Search for Related Content PubMed PubMed Citation Articles by Diamandis, E. P. Related Collections Proteomics and Protein Markers Automation and Analytical Techniques

Oncopeptidomics: A Useful Approach for Cancer Diagnosis?

Department of Pathology, and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, ONT M5G 1X5 Canada
Department of Laboratory Medicine, and Pathobiology, University of Toronto, Toronto, ONT, Canada, E-mail ediamandis@mtsinai.on.ca

The first 300 words of the full text of this article appear below.

In this issue of Clinical Chemistry, Mary Lopez and colleagues (1) describe novel methods for isolation of protein-bound peptides from serum and their characterization by mass spectrometry. Lopez et al. used selected peptide combinations to develop a new profiling method for ovarian cancer diagnosis. To put this advance into perspective, I will briefly summarize relevant previous literature on diagnostic applications of serum proteomic and peptidomic profiling by mass spectrometry.

Approximately 5 years ago, a new approach for diagnosing ovarian cancer, by use of SELDI-TOF mass spectrometry, was proposed by the coauthors of the article under discussion (2). It was then hypothesized that proteins or protein fragments released by tumor cells or their microenvironment may enter the general circulation. By the use of a SELDI chip, proteins or peptides could be extracted from crude serum and used for diagnostic purposes with the aid of mass spectrometry and a mathematical algorithm. Similar methods have subsequently been used to diagnose numerous other malignancies, such as breast, prostate, bladder, pancreatic, head and neck, lung, liver, and nasopharyngeal cancers, as well as gliomas and melanomas, with impressive diagnostic sensitivities and specificities. This method has enjoyed ample coverage in scientific journals, the media, and international conferences (3).

This author and others have criticized this diagnostic approach for methodological shortcomings and bioinformatic artifacts (4)(5)(6)(7)(8)(9). During the last 5 years, healthy debates have been conducted in journals (including this one) and at conferences (10)(11). An independent validation study would be the best test for this technology. As yet, however, no published validation is available to confirm that these methodologies are working. The proponents of the serum proteomic profiling methods for cancer diagnostics have now turned . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				G. M. Fiedler, A. B. Leichtle, J. Kase, S. Baumann, U. Ceglarek, K. Felix, T. Conrad, H. Witzigmann, A. Weimann, C. Schutte, et al. Serum Peptidome Profiling Revealed Platelet Factor 4 as a Potential Discriminating Peptide Associated with Pancreatic Cancer Clin. Cancer Res., June 1, 2009; 15(11): 3812 - 3819. [Abstract] [Full Text] [PDF]

				J. Villanueva, A. Nazarian, K. Lawlor, S. S. Yi, R. J. Robbins, and P. Tempst A Sequence-specific Exopeptidase Activity Test (SSEAT) for "Functional" Biomarker Discovery Mol. Cell. Proteomics, March 1, 2008; 7(3): 509 - 518. [Abstract] [Full Text] [PDF]

				R. E. Banks Preanalytical Influences in Clinical Proteomic Studies: Raising Awareness of Fundamental Issues in Sample Banking Clin. Chem., January 1, 2008; 54(1): 6 - 7. [Full Text] [PDF]